A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer

NCT03403712 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

404

Enrollment

INDUSTRY

Sponsor class

Conditions

Chemotherapy-induced Nausea and Vomiting

Interventions

DRUG: fosnetupitant/ palonosetron
DRUG: netupitant/palonosetron
DRUG: dexamethasone

Sponsor

Helsinn Healthcare SA

Collaborators

[object Object]
[object Object]